Table 3 Analysis of factors associated with poor OS.

From: A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices

Parameters

 

Univariate analysis

Multivariate analysis

HR

95% CI

p

HR

95% CI

p

Age (years)

 > 65 vs.≦65

2.129

1.515–2.991

 < 0.001

1.721

1.213–2.441

0.002

Sex

Male vs. Female

0.993

0.708–1.392

0.968

   

HBsAg (+)

No vs. Yes

1.808

1.292–2.532

0.001

   

Anti-HCV (+)

Yes vs. No

1.104

0.801–1.521

0.547

   

Albumin (g/dL)

≦3.5 vs. > 3.5

1.972

1.421–2.737

 < 0.001

   

Bilirubin (mg/dL)

 > 1.6 vs.≦1.6

1.481

1.034–2.122

0.032

   

ALT (U/L)

 > 40 vs.≦40

0.852

0.616–1.178

0.334

   

ALK-P (U/L)

 > 100 vs.≦100

0.978

0.678–1.412

0.907

   

PT-INR

 > 1.1 vs.≦1.1

1.232

0.890–1.705

0.209

   

AFP (ng/ml)

 > 20 vs.≦20

1.217

0.877–1.690

0.241

   

Multiple Tumors

Yes vs. No

1.549

1.076–2.230

0.019

1.630

1.129–2.354

0.009

Tumor size (cm)

 > 3 vs.≦3

0.784

0.538–1.142

0.205

   

Treatment modality

RFA vs. SR

2.658

1.698–4.159

 < 0.001

2.271

1.427–3.616

0.001

PLT (× 1000/mm3)

≦100 vs. > 100

1.389

0.975–1.980

0.069

   

ALBI grade

2 + 3 vs. 1

1.920

1.270–2.903

0.002

1.583

1.032–2.427

0.035

All peri-procedural morbidity

Yes vs. No

1.250

0.802–1.950

0.324

   

Major morbidity

Yes vs. No

3.298

1.859–5.851

 < 0.001

3.201

1.774–5.777

 < 0.001

High risk EV

Yes vs. No

1.395

0.984–1.979

0.062

   

Presence of GV

Yes vs. No

1.449

0.974–2.157

0.067

   

EV prophylaxis

No vs Yes

1.362

0.988–1.876

0.059

   
  1. HR hazard ratio; CI confidence interval; HBsAg hepatitis B surface antigen; HCV hepatitis C virus; ALT alanine aminotransferase; ALK-P alkaline phosphate; PT INR prothrombin time international normalized ratio; AFP alpha-fetoprotein; RFA radiofrequency ablation; SR surgical resection; PLT platelet; ALBI Albumin-Bilirubin.
Back to article page